Humboldt
Venture capitalNew York · Pre-Seed–Series A · 3 people tracked
Also known as HUMBOLDT CAPITAL, LLC
Investment thesis
Exclusive synthetic biology investor focused on companies replacing industrial inputs with biology-based alternatives, led by a UCSF-trained PhD cell biologist offering deep research expertise and global Latin America–Europe reach.
Source: firm website, verified Aug 18, 2026.
Team · 3 people
from public directories
What they invest in
from 15 of 20 portfolio companiesBiotech ×13Healthtech ×5AI & Machine Learning ×4Deep Tech ×4Medical Devices ×4Climate Tech ×2FoodTech ×2New Materials ×2
HQs:United States×9
Investments · 20 tracked
founders shown can be your intro pathBy year:2023 · 12020 · 12018 · 24 dated
Berkeley, US
Brian Thomas(Executive Officer, Director, Promoter)
BoardAndrew Farquharson(Director)Jak Knowles(Director)
Board seatSebastian Bernales· per SEC Form D · $100M raise · filed Jan 2023
Co-investorsVHM
HealthtechSan Leandro, US
Zachary Sun(Executive Officer, Director)Michael Nemzek(Executive Officer, Director)Corinna Chen(Director)
Board seatFrancisco Dopazo· per SEC Form D · $17.6M raise · filed Sep 2023
Affini-T Therapeutics develops TCR-based immunotherapies aimed at treating solid tumors, using two complementary therapeutic modalities.
BiotechHealthtechLongevity
Co-investorsAgent CapitalOlive Tree Capital
Ansa provides an enzymatic DNA synthesis platform that directly synthesizes complex sequences up to 900 bp and delivers constructs up to 50 kb without assembly-based methods.
BiotechDeep TechHealthtechEmeryville, US
Dan Lin-Arlow(Founder)inSebastian Palluk(Founder)inDaniel Lin-Arlow(Executive Officer, Director)Daniel Hillel Lin-Arlow(Executive Officer, Director)Jason T. Gammack(Executive Officer, Director)
BoardYanniv Dorone(Director)
Co-investorsCarbon SiliconDauntless VenturesFifty YearsMetaplanetY CombinatorFall Line Capital+2 more
Co-investorsAgFunderAngel Collective Opportunity FundArgonautic VenturesFifty YearsGermin8 VenturesHorizons Ventures+3 more
Cellineobio develops cell engineering and bioprocess technology platforms.
AI & Machine LearningBiotechDeep TechMedical DevicesCambridge, US
Nabiha Saklayen, PhD(Co-Founder & CEO)inMarinna Madrid, PhD(Co-Founder & Chief Product Officer)Nabiha Saklayen(Executive Officer, Director)Matthias Wagner(Executive Officer, Director)
Co-investors8VCFelicis VenturesKhosla VenturesThe Engine Ventures
Debut develops an AI-powered biomanufacturing platform that uses genomics and biotechnology to discover, validate, and scale novel bioactive ingredients for the beauty industry, including skincare, hair, and body care products.
AI & Machine LearningBiotechConsumerDeep TechSan Diego, US
Joshua Britton(Founder)
Co-investorsGS FuturesMaterial ImpactBreakout VenturesKdT VenturesSandbox IndustriesACVC Partners+8 more
Endpoint Health develops therapeutics and therapy-guiding diagnostic tests personalized to each patient's biology for immune-driven critical and chronic illnesses such as sepsis, ARDS, rheumatoid arthritis and inflammatory bowel disease.
BiotechDigital HealthHealthtech
Co-investorsWireframe Ventures
Finch Therapeutics is a life sciences company focused on the development and protection of drug-related intellectual property and therapeutics within the biotechnology and pharmaceutical industry.
BiotechHealthtechMedical DevicesSomerville, US
Mark Smith(Executive Officer, Director)Matt Blischak(Chief Executive Officer)R. J. Price(Director)Jeffery A. Smisek(Director)Andrew Mulderry(Director)James Burgess(Director)
Co-investorsB3 HoldingOctave Ventures LlcOCV PartnersOMX VenturesShumway Capital
Finless Foods develops cell-cultivated seafood alternatives, starting with Pacific bluefin tuna, aimed at consumers seeking sustainable options that reduce pressure on wild fish stocks.
BiotechClimate TechFoodTech
Brandon Chen(Co-Founder & CEO)Brian Wyrwas(Co-Founder & CSO)Michael Selden(Co-Founder & Advisor)
Co-investorsAt One VenturesAurum Venture PartnersBabel VenturesBlue Horizon CorporationBlue Revolution Investments G.P.Endurance28+7 more
GCTx develops an induced pluripotent stem cell (iPSC) programming platform called TFome™ that uses synthetic biology, gene editing, and machine learning to improve cell therapy development and scaling.
AI & Machine LearningBiotechMedical DevicesCambridge, US
George Church(Co-Founder & Scientific Advisor)Parastoo Khoshakhlagh(Chief Executive Officer & Co-Founder)Alex Ng(Chief Innovation Officer & Co-Founder)
Co-investorsAndreessen HorowitzGlobal BrainMedical Excellence Capital
Geltor develops biodesigned proteins, including collagen products such as PrimaColl, used as active ingredients in cosmetics and personal care formulations.
BiotechNew MaterialsWellness & Fitness
Co-investorsAgronomicsAlwyn CapitalArgonautic VenturesBaruch Future VenturesBlue Horizon CorporationCavallo Ventures+12 more
Co-investorsBackedHAWKTAILFuture Positive Capital
Metagenomi Therapeutics is an in vivo genome editing company that uses genetic material sourced from natural environments (metagenomics) to develop a toolbox of editing tools for deletion, integration, and correction of genetic mutations.
BiotechDeep TechMedical Devices
Co-investorsCatalio Capital Management, LPRA CapitalSozo VenturesAgent Capital
Co-investorsID345Sun Mountain CapitalOS Fund
Mission Barns produces cultivated meat products, primarily pork-based items like meatballs, bacon, and sausages, combining lab-grown pork fat with plant protein for consumers seeking sustainable alternatives to conventional meat.
Climate TechFoodTechBerkeley, US
Ilan Eitan Fischer(Executive Officer, Director)
BoardDavid Bowman(Director)
Co-investorsAir Street CapitalBabel VenturesBetter Ventures Central LlcBloom8Blue Ledge CapitalJoyance Partners+6 more
MycoWorks produces Reishi, a premium biomaterial made from Fine Mycelium, used as a sustainable leather alternative in furniture, design, and automotive products.
BiotechCircular EconomyNew MaterialsEmeryville, US
Philip Ross(Director)Michael Lindheim(Executive Officer)Matthew Scullin(Executive Officer, Director)
BoardKiersten Stead(Director)inThomas Grotkjaer(Director)
Co-investorsDCVC (Data Collective)Hemisphere Ventures LLCWireframe Ventures8VCAgFunderDCVC Bio+3 more
Phage Lab develops solutions to address bacterial outbreaks using a One Health approach, bringing together around 100 scientists and professionals from multiple disciplines in animal health and microbiology.
AgTechAI & Machine LearningBiotech
Pablo Cifuentes Palma(Founder)inHans Pieringer(Founder)in
Co-investorsCollaborative FundInvexor Venture PartnersNazcaThe Yield Lab LatamKaszek Ventures
Co-investorsSustainable Food VenturesCleveland AvenueMAYA Capital VenturesTrousdale Ventures
Tierra Biosciences develops high-performance protein design technology, serving biotechnology and pharmaceutical industries.
Biotech
Co-investorsBeresford VenturesCreative VenturesFifty YearsFREEFLOWMaterial ImpactKdT Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 1
IPOs and acquisitions across the tracked portfolioMetagenomi TechnologiesNASDAQ: MGX
Portfolio news
latest coverage across their companiesPhage Lab · latamrepublic.com · Apr 10, 2026
GC Therapeutics · nasdaqprivatemarket.com · Apr 3, 2026
Ansa Biotechnologies · drugdiscoverynews.com · Oct 9, 2025
Mission Barns · sfexaminer.com · Sep 10, 2025
Frequently asked questions
- What stage does Humboldt invest at?
- Humboldt invests at the Pre-Seed, Seed, Series A stages.
- What is Humboldt's typical check size?
- Humboldt typically writes checks of $100K – $5M.
- What sectors does Humboldt focus on?
- Humboldt focuses on AgTech, AI & Machine Learning, Biotech, FoodTech, Hardware, Healthtech, New Materials.
- Where is Humboldt located?
- Humboldt is headquartered in New York, US.
- Does Humboldt lead rounds?
- Humboldt typically participates in rounds rather than leading them.
Media · Podcasts & interviews
featuring the teamVentures #7 w/ Francisco Dopazo - General Partner @ Humboldt Fund | BIOS
BIOS · Francisco Dopazo
Co-investors · 5
RA Capital invests in public and private healthcare and life science companies developing pharmaceuticals, medical devices, and diagnostic tools. The firm operates as a crossover fund across multiple investment stages.
Causal is a financial planning and analysis platform that enables finance teams to move beyond traditional spreadsheet-based planning by integrating data from multiple sources and providing dynamic forecasting, budgeting, and scenario planning capabilities.
Tencent is a Chinese technology company operating consumer products such as WeChat/Weixin and Tencent Games, business services including Tencent Cloud, and technology research units like Tencent Media Lab and Ethereal Lab.
Apollo Health Ventures is a biotech-focused investor that combines traditional funding with venture building to back transformative healthcare and longevity companies in Europe and the US.
Broadview Ventures is an impact investor focused on accelerating the development of technology for the diagnosis and treatment of cardiovascular disease and stroke through targeted investments.
Firms observed investing alongside Humboldt, from public investor directories. Shared companies are the overlap with Humboldt's recorded portfolio.
Similar investors
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
Snatched Ventures is a San Francisco-based early-stage venture capital firm backing DeepTech startups focused on sustainable innovation and operational transformation. It is led by a two-GP team combining corporate development and institutional investment management experience.
SOSV is a deep tech venture capital firm that makes first-check pre-seed investments and follow-on rounds in startups focused on human and planetary health, providing lab space and hands-on support at its US locations.
Rockies Venture Club is an angel investor network of 100+ active members focused on Seed to Series A opportunities, offering due diligence, syndication nationwide, and educational programming for investors and entrepreneurs.
Unruly Capital is a venture firm that backs founders working on ideas that seem too early or unconventional but are expected to become mainstream within a decade, focusing on frontier technology themes.